UPDATE: Baird Starts Decibel Therapeutics Inc (DBTX) at Outperform
Get Alerts DBTX Hot Sheet
Rating Summary:
3 Buy, 4 Hold, 0 Sell
Rating Trend: Up
Today's Overall Ratings:
Up: 11 | Down: 12 | New: 13
Join SI Premium – FREE
Baird analyst Jack Allen initiates coverage on Decibel Therapeutics Inc (NASDAQ: DBTX) with a Outperform rating and a price target of $21.00.
The analyst comments "Decibel's diverse otology pipeline provides a number of ways to win. Starting with DB-OTO, the lead gene therapy, here we are encouraged by the preclinical data and believe that congenital OTOF deficiency is an indication well suited for gene therapy. Shifting gears to DB-020, Decibel's otoprotective therapy, we view this program as fairly derisked given Fennec's positive STS data. With clinical readouts expected over the course of the next 12-18months, we believe positive data from either one of these programs could result in significant appreciation of shares."
For an analyst ratings summary and ratings history on Decibel Therapeutics Inc click here. For more ratings news on Decibel Therapeutics Inc click here.
Shares of Decibel Therapeutics Inc closed at $7.47 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- META to capture largest share of users, SNAP to benefit from ad budget shifts - Canaccord Genuity weighs in on TikTok ban
- Merck (MRK) PT Raised to $143 at Truist Securities
- Avery Dennison (AVY) PT Raised to $230 at Baird
Create E-mail Alert Related Categories
Analyst Comments, New CoverageRelated Entities
Robert W BairdSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!